RB1 and triple-negative breast carcinoma: Moreover, RB1 loss (in combination with impaired BRCA-mutant signature and high SLFN11 expression) was highly predictive for the response of patient-derived xenografts of triple-negative breast cancer to irinotecan (SN-38 is the active metabolite of irinotecan) [41].